KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Cash & Equivalents (2016 - 2025)

Quest Diagnostics' Cash & Equivalents history spans 17 years, with the latest figure at $420.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 23.5% year-over-year to $420.0 million; the TTM value through Dec 2025 reached $420.0 million, down 23.5%, while the annual FY2025 figure was $420.0 million, 23.5% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $420.0 million at Quest Diagnostics, down from $432.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.2 billion in Q1 2021 and bottomed at $126.0 million in Q2 2023.
  • The 5-year median for Cash & Equivalents is $511.5 million (2024), against an average of $535.6 million.
  • The largest annual shift saw Cash & Equivalents crashed 84.05% in 2023 before it surged 434.27% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $872.0 million in 2021, then crashed by 63.88% to $315.0 million in 2022, then surged by 117.78% to $686.0 million in 2023, then fell by 19.97% to $549.0 million in 2024, then decreased by 23.5% to $420.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's Cash & Equivalents are $420.0 million (Q4 2025), $432.0 million (Q3 2025), and $319.0 million (Q2 2025).